Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Total Current Liabilities (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Total Current Liabilities for 3 consecutive years, with $33.8 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities fell 17.02% to $33.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $33.8 million through Dec 2025, down 17.02% year-over-year, with the annual reading at $33.8 million for FY2025, 17.02% down from the prior year.
  • Total Current Liabilities for Q4 2025 was $33.8 million at Inhibrx Biosciences, down from $36.0 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $56.3 million in Q4 2023, with the low at $33.8 million in Q4 2025.
  • Average Total Current Liabilities over 3 years is $41.6 million, with a median of $39.9 million recorded in 2024.
  • The sharpest move saw Total Current Liabilities dropped 27.67% in 2024, then decreased 0.29% in 2025.
  • Over 3 years, Total Current Liabilities stood at $56.3 million in 2023, then decreased by 27.67% to $40.7 million in 2024, then fell by 17.02% to $33.8 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $33.8 million, $36.0 million, and $38.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.